Rivaroxaban 2.5mg
Rivaroxaban 2.5 mg co-administered with aspirin, for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events, is reimbursed on the Community Drug Schemes from 1st October 2022. A Managed Access Protocol (MAP) is in place for rivaroxaban 2.5 mg. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of rivaroxaban 2.5 mg on the Community Drug Schemes.
All clinicians (i.e. GPs and hospital prescribers), can submit an application for individual reimbursement approval of rivaroxaban 2.5 mg. A separate application for reimbursement approval must be submitted for each patient.
A copy of the MAP for rivaroxaban 2.5 mg, correspondence issued to prescribers, and Anticoagulation Prescribing Tips, can be found in the Related Files section below.
For further information, please contact mmp@hse.ie.